NEW YORK (GenomeWeb) – N-of-One announced today that it has signed a deal to provide Macrogen with clinical interpretation services for its clinical next-generation sequencing-based cancer panels.
"The partnership between Macrogen and N-of-One will further strengthen Macrogen's growth in the clinical setting to enable accessibility of personalized medicine," Macrogen CEO Sang Tae Park said in a statement. "It will deliver comprehensive and clear reports including therapeutic options suited to each patient with information of molecular/clinical relevance and eligible clinical trials for the rapidly growing number of clinical cancer NGS test results."
Specific terms of the arrangement were not disclosed.
The deal marks the latest in a series for N-of-One. Last year, the company inked agreements to provide interpretation services to WuXi, Spectrum Health, GenomiCare, CompanionDx, and Affymetrix.